Quince Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771. This patent application is entitled 'Process for the Preparation of Erythrocytes Loaded With One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes'.
The newly allowed application specifically covers the method of treating patients with Ataxia-Telangiectasia (A-T) using the EryDex process. This allowance is expected to extend patent claims related to this method of use into 2036 in the U.S., significantly strengthening the intellectual property protection for EryDex.
Charles Ryan, J.D., Ph.D., Quince's President, stated that this allowance strengthens market exclusivity and validates the proprietary AIDE technology platform. The resulting patent is expected to be listable in the FDA's Orange Book, providing Quince with notice of future generic applicants and other stay provisions under the Hatch-Waxman Act.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.